Toggle menu

COPS

Start date:
30/07/2016
End date:
31/09/2017
Co-ordinated by:
Royal Infirmary of Edinburgh
Main trial site:
RIE

This study contributes to the work of Dr Frank Prior who is developing a tool to be used in the treatment of shock.

It is known that shock creates a set of internal conditions that affect vasculature and that these conditions can vary over time and are dependent on the type of shock. This tool reveals the condition of the vasculature and therefore informs which fluid and drugs are best advised for that patient at that time. The tool is based on patient pore size, Mean Osmotic Pressure (MOP) and Mean Arterial Pressure (MAP). As the ability to measure MOP is expensive and rare in the UK, this study is an unique opportunity to investigate if calculating MOP from biochemistry results is accurate by comparing measured and calculated MOP. This is an observational study recruiting 20 healthy volunteers from the orthopaedic pre-assessment clinic. We are very excited about this study as the tool would given clinicians the ability to treat patients with regard to their individual pathophysiology and is therefore in line with a precision medicine based approach.

This study will commence on the 30th May 2016.

Chief Investigator

Dr Gareth Clegg

Senior Lecturer at the University of Edinburgh & Honorary Consultant in Emergency Medicine

Research Team

Dr Frank Prior PhD

Pharmacist

Allan MacRaild

Stroke Lead Research Nurse

More EMERGE Trials

ETNA: Edinburgh Transient and Neurological attack: A Cohort Study

Patients frequently present with minor neurological symptoms where a diagnosis of transient ischaemic attack (TIA) or minor stroke is difficult to make positively or to exclude reasonably. For these patients, clinicians are uncertain whether they should: (a) reassure most patients that their symptoms are benign; (b) treat most patients with antiplatelet or other vascular prevention; or (c) stratify stroke risk further using clinical features or brain imaging.
This is important because clinical diagnosis is difficult. Mis-diagnosis is not infrequent and leads to harm from preventable recurrent stroke and costs to health systems from extra care and legal liabilities.
All ETNA participants will receive an MRI scan and the study aims to establish the feasibility and methods for a larger study of diagnostic utility of MR brain imaging and estimate the effects of MRI on clinician decision making.
This study has been recruiting in the Emergency Dept, inpatient wards and TIA clinics since August 2018. We aim to recruit 270 participants and have almost reached our target!

Read more

ETNA

Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.

Read more

NOVEL Study

Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2 Trial

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)